Performance and Sport Rehabilitation Laobratory. University of Castilla-La Mancha
Toledo, 45004, Spain
NCT Number: NCT06318312
The goal of this clinical trial is to determine the effects of different hypoxia exposures (FiO2 = 11%, 13%, 15%, and 21%) on cognitive performance in healthy adults. The main questions it aims to answer are:
* What is the best hypoxia exposure to improve reaction time, anticipation, attention and memory tasks? * Which hypoxia exposure causes the greatest detriments in cognitive function?
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Not applicable
Toledo, 45004, Spain
Participants will completed four trials in a single-blinded crossover randomised control trial. In the first session, individuals familiarised with the different cognitive tests and hypoxic exposures. In the next four experimental trials (separated by 1 week), participants arrived at the laboratory and rested in a seated for 10 min. The vital signs (i.e., SpO2, HR, blood pressure) and Lake Louise Score were recorded prior to mask placed and start with in one of the four conditions: a) PLA/NOR, b) FiO2=15%, c) FiO2=13% or FiO2=11%. In this hypoxic condition the participant will spend a total of 45 min, of which 30 min was at rest, and the other 15 min was performing the cognitive tasks (i.e., memory test, go/no-go test, eriksen flanker test, anticipation task and reaction time test).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
Other names: hypoxic exposure
Time frame: During each hypoxic condition
To study the modulation of memory storage processes, three 20-item word lists were created. Each word in the list will be presented for 5 s. This will be followed by a 100 s memory consolidation interval, after which there will be a 120 s period in which as many words as the participants can remember will be written down (First time). After 15 min, participants will perform a recall task (Second time) in which they will have to rewrite all the words they remember at that time.
Time frame: During each hypoxic condition
The ability of maintaining the attention and inhibiting an appropriate response will be measured by "Go/No-Go Test" [fastest, slowest, and average response time (in seconds), and successful attempts (percentage; %)] and "Eriksen Flanker Test" [congruent and incongruent reaction time (in seconds)].
Time frame: During each hypoxic condition
Visual acuity related to hand-eye coordination and anticipation will be assessed using the Bassin Anticipation Timer instrument. The best anticipation time (in seconds) of each condition (5, 10 and 15 mph) will be taken.
Time frame: During each hypoxic condition
Reaction time (in seconds) shall be assessed with the Dynavision™ D2 Visomotor Device using the "Reaction Time Test". In this test the fastest visual, motor and physical reaction time will be measured.
University of Castilla-La Mancha
Other
Effects of Different Hypoxia Exposures on Cognitive Performance in Healthy Adults
Acronym: HYPCOG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07720960
Erythropoiesis, Hypoxia
Elche, Alicante, Spain
View Trial DetailsNCT05767385
Cardiovascular Abnormalities, Cardiovascular Diseases
San Francisco, California, United States
View Trial DetailsNCT01542177
Digestive System Diseases, Digestive System Neoplasms
Toronto, Ontario, Canada
View Trial DetailsNCT05354648
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details